STOCK TITAN
  1. Home
  2. ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

ATRX OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
0 15 sessions, October 7, 2025 to October 7, 2026
Largest daily move
+0% close of October 23, 2025

Company Description

Adhera Therapeutics (OTC: ATRX) is classified in the biotechnology industry within the Healthcare sector.

This page collects what Stock Titan holds for ATRX, including price data, latest news, and financial highlights.

Stock Performance

Chart
$0.0001
No recent trading
Last close: October 7, 2026
-
1 year to October 7, 2026
-
Market Cap
7.2M
Shares outstanding

Adhera Therapeutics (ATRX) closed at $0.0001 on October 7, 2026.

See what a $1,000 investment in ATRX would be worth today

Average down calculator for ATRX

Latest News

View All
0.00%

Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes

clinical trial
+10.77%

Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist

management
+16.67%

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

acquisition
+15.55%

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

management
-8.75%

Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board

management
+10.09%

Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

+3.52%

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

0.00%

Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

management
-10.31%

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

+26.25%

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease

clinical trial

Adhera Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, management, acquisition. View all ATRX news →

SEC Filings

No SEC filings available for ATRX.

Financial Highlights

View Full Financials
0.00
Current Ratio
—
Revenue (FY2022)
—
Net Income (FY2022)
—
Diluted EPS (FY2022)
—
Operating Cash Flow
—
Net Profit Margin

Upcoming Events

No upcoming events scheduled for ATRX.

Related Stocks

EFTR eFFECTOR Theraputcs Inc
$940.0
YECO Yulong ECO Materials Ltd
$1.0K
CLABF Core One Labs Inc
VRPX Virpax Pharms Inc
$372.0
WSNAF Wesana Health Holdings Inc
$347.0
RGRX RegeneRx Biopharms Inc
$1.6K
EVLO Evelo Biosciences Inc
IVRN Innoveren Scientific Inc
$1.9K

ATRX Company Profile & Sector Positioning

Adhera Therapeutics (ATRX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing ATRX often look at related companies in the same sector, including eFFECTOR Theraputcs Inc (EFTR), Yulong ECO Materials Ltd (YECO), Core One Labs Inc (CLABF), Virpax Pharms Inc (VRPX), and Wesana Health Holdings Inc (WSNAF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATRX's relative position within its industry.

Frequently Asked Questions

Adhera Therapeutics (ATRX) has no recent trading. Its last close was $0.0001 on October 7, 2026.

The current ratio of Adhera Therapeutics (ATRX), current assets divided by current liabilities, was 0.00 at the end of FY2022, its most recent completed fiscal year. Learn about liquidity ratios.